2026-04-29T16:12:51+08:002024-07-10|
Contact Information
Title
Assistant Professor
Office
(Address) E12-2013 / (Phone) +853 8822 4938
Lab
(Address) N22-3037a / (Phone) +853 8822 2525
Team Office
(Address) N22-3038 / (Phone) +853 8822 2623
Email
zhenghaitang@um.edu.mo
Consultation Hours

Wed 16:00 – 17:00, Thu 10:00 – 11:00

Teaching

HSCI8006 Advanced Molecular Cell Biology

GEST1002 Quantitative Reasoning for Social Science
HSCI2002 General and Clinical Microbiology

Research Team
Name Position Office Phone Email
Buxi FANPhD Studentyc57692@um.edu.mo
Buxi FANPhD Studentyc57692@um.edu.mo
Jianping WUPhD Student
Linna GUPhD Studentyc57669@um.edu.mo
Linna GUPhD Studentyc57669@um.edu.mo
Yan GAOPhD Studentyc57655@um.edu.mo
Yan GAOPhD Studentyc57655@um.edu.mo
Yongbo WANGPhD Studentyc58614@um.edu.mo
Yongbo WANGPhD Studentyc58614@um.edu.mo
Education
PhD University of Macau, China (2017)
MMed Beijing University of Chinese Medicine, China (2013)
BEng Beijing University of Chinese Medicine , China (2011)
Positions
2024 – Present Assistant Professor, Faculty of Health Sciences, University of Macau
2023 – 2024 Research Associate, Montreal Clinical Research Institute, Montreal, Quebec, Canada
2017 – 2023 Postdoctoral Fellow, Montreal Clinical Research Institute, Montreal, Quebec, Canada
Research Interests
Prof Tang’s research focuses on cancer immunotherapy and therapeutic drug development. His work includes:

  1. Providing an in-depth mechanistic understanding of immune checkpoints to enable the rational development of first-in-class monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
  2. Screening for novel immune checkpoints using CRISPR with specific sgRNA libraries for cancer therapy.

His research is supported by grants as PI, such as the Young Scientists Fund Scheme (Category B) (原優秀青年科學基金) and the Science and Technology Development Fund (FDCT) of Macau etc.
Representative Publications
First and co-first# author articles, Corresponding* author articles :

  1. Z Tang*, A Veillette: Inhibitory immune checkpoints in cancer immunotherapy. Science Immunology 2025, 10 (111), eadv6870
  2. Z. Tang, M-C Zhong, J. Qian, J. Dou, L. S. Wong, J. Li, C. C. Galindo, D. Davidson, A. Veillette: Anticancer immune responses are hindered by cis interaction of inhibitory checkpoint SIRPα. Science Immunology 2025, 10 (112), eadv5085
  3. Tang Z, Zhong MC, Qian J, Galindo CC, Davidson D, Li J, Zhao Y, Hui E, Veillette A: CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress anti-tumor immunity. Nature Immunology 2023, 24: 2032–2041.
  4. Tang Z, Veillette A: Combining a first-in-class SLAMF7 antibody with SIRPα blockade for anti-tumor immunity. Nature Immunology 2023, 24: 1978–1979.
  5. Tang Z, Veillette A: Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells. Nature Nanotechnology 2022, 17:1243-4.
  6. Tang Z#, Davidson D#, Li R, Zhong MC, Qian J, Chen J, Veillette A: Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. Cell Reports 2021, 37:110111.
  7. Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ: Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Letters 2018, 412:1-9.
  8. Tang ZH, Lu JJ: Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Letters 2018, 420:242-6.
  9. Tang ZH#, Cao WX#, Wang ZY, Lu JH, Liu B, Chen X, Lu JJ: Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells. Redox Biology 2017, 12:367-76.

Other articles:

  1. A Veillette, J Li, CC Galindo, D Davidson, Z Tang: Targeting phagocytosis checkpoints for cancer immunotherapy. Nature Reviews Cancer 2026 26 (3), 185-199
  2. B Li, M-C Zhong, C. C. Galindo, J. Dou, J. Qian, Z. Tang, D. Davidson, A. Veillette: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer. Nature 2026, 652, 722–730
  3. K Zhu, J Dou, B Li, J Qian, MC Zhong, Z Tang, Y Lu, A Veillette: CD2 and its ligands are involved in development and activation of MAIT cells, Journal of Experimental Medicine 2025, 222 (12), e20250431
  4. J Li, Z Wang, X Qin, MC Zhong, Z Tang, J Qian, J Dou, T Hussell, PD King, J. A Nunès, Y. Yamanashi, D. Davidson, A. Veillette: CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth. Nature Communications 2025, 16 (1), 5145
  5. WQ Deng, ZH Ye, Z Tang, XL Zhang, JJ Lu: Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases. Acta Pharmaceutica Sinica B 2025, 15 (2), 757-791
  6. Li B, Lu Y, Zhong MC, Qian J, Li R, Davidson D, Tang Z, Zhu K, Argenty J, de Peredo AG, Malissen B, Roncagalli R, Veillette A: Cis interactions between CD2 and its ligands on T cells are required for T cell activation. Science Immunology 2022, 7:eabn6373.
  7. Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ: Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology 2020, 175:113921.
  8. Veillette A, Tang Z: Signaling Regulatory Protein (SIRP)alpha-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition. Journal of Clinical Oncology 2019, 37:1012-4.
  9. Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, Lu JJ: MLKL mediates apoptosis via a mutual regulation with PERK/eIF2alpha pathway in response to reactive oxygen species generation. Apoptosis 2018, 23:521-31.
  10. Wang YF, Xu YL, Tang ZH, Li T, Zhang LL, Chen X, Lu JH, Leung CH, Ma DL, Qiang WA, Wang YT, Lu JJ: Baicalein Induces Beclin 1- and Extracellular Signal-Regulated Kinase-Dependent Autophagy in Ovarian Cancer Cells. American Journal of Chinese Medicine 2017, 45:123-36.
Research Grants
01/2026 – 12/2028 PI, Young Scientists Fund (Type B) of the National Natural Science Foundation of China (82522088)
05/2025 – 05/2028 PI, Macao Science and Technology Development Fund (0090/2024/RIB2)
01/2026 – 12/2027 PI, University of Macau, Multi-Year Research Grant – General Research Grant (MYRG-GRG2025-00072-FHS)
08/2024 – 08/2027 PI, University of Macau, University of Macau Development Foundation Technology and Innovation Start-up Funding Scheme (UMDF-TISF/2025/002/FHS).
08/2024 – 08/2027 PI, University of Macau, Start-Up Research Grant (SRG2024-00027-FHS)
2019 PI, Cole Foundation, Canada, Targeting the SIRP α-CD47 Immune Checkpoint Against non Hodgkin’s Lymphoma
Awards
2018 Angelo Pizzagalli Scholarship, Montreal Clinical Re search Institute, Montreal, Quebec, Canada
2013 – 2016 University of Macau PhD Scholarship, University of Macau, Macau , China
Professional Activities
Youth Editorial Board Member
2022 – Present Chinese Medicine (IF=4.9)
Journal Paper Reviewer
  • Acta Pharmaceutica Sinica B
  • Biomedicine & Pharmacotherapy
  • Biomedical and Environmental Sciences
  • Cancer Letters
  • Cell Communication and Signaling
  • Cell Reports
  • Chinese Journal of Natural Medicines
  • Frontiers in Immunology
  • Heliyon
  • Journal of Experimental & Clinical Cancer Research
  • Molecular and Cellular Biology
  • Phytomedicine
  • Phytotherapy Research